michel-de-rosen

Pharnext adds industry veteran to board

pharmafile | December 10, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Michel de Rosen, pharnext 

France-based clinical stage biopharma firm Pharnext has appointed Michel de Rosen to its board of directors.

For nearly 25 years de Rosen has held various executive positions at Rhone-Poulenc, in particular at its pharma subsidiary Rhone-Poulenc Rorer – now known as Sanofi – and then at ViroPharma.

He began his career at the ‘Inspection Generale des Finances’ of the French Ministry of Economy and Finance, before rising to director in the cabinet of Alain Madelin, minister of industry and telecommunications from 1986 to 1988.

Advertisement

While at Rhone-Poulenc from 1983 to 1999 de Rosen successively served as president and chief executive at Pharmuka, Rhone-Poulenc Fibers and Polymers, and then Rhone-Poulenc Rorer in the US.

From 2000 to 2008 as chief executive of ViroPharma he oversaw the company that was recently purchased by Shire.  After 15 years in the US de Rosen returned to France. Since 2009 he has been chief executive of Eutelsat Communications, the largest operator of satellites in Europe.

Chairman  and  chief  executive  of  Pharnext, Daniel  Cohen,  says: “Michel de Rosen’s nomination to our board of directors falls within our wish to accelerate Pharnext’s development both in France and abroad. His achievements at Rhone-Poulenc Rorer and ViroPharma are very impressive. His international expertise will prove valuable to us in our development dynamics.”

Related Content

Pharnext CMT drug shows positive Phase III results

Pharnext SA’s PXT3003 treatment for patients with Charcot-Marie-Tooth Disease (CMT) has shown positive interim results …

The Gateway to Local Adoption Series

Latest content